Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

End-of-day quote. End-of-day quote  - 09/23
410.39 USD   +0.58%
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for ..
09/20 REGENERON PHARM : Teva buys rights to Regeneron chronic pain drug fo..
09/20 Bayer raises sales targets for top-selling drugs after Monsanto d..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Sanofi : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Review

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/26/2016 | 07:49am CEST

By Inti Landauro

PARIS--The U.S. Food and Drug Administration is to undertake a priority review of a treatment for atopic dermatitis, a chronic inflammatory skin disease, according to pharmaceutical firms Sanofi SA (>> Sanofi) and Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) which make the drug.

The two companies had said in June that a series of trials showed the treatment, known as dupilumab, combined with topical corticosteroids significantly improved the condition of a group of patients suffering from atopic dermatitis.

Back in 2014, the FDA had granted "breakthrough therapy" designation to dupilumab.

Large pharmaceutical companies like Sanofi are rushing to get new drugs to market to offset falling revenues from top-selling drugs whose patents recently expired.

-Write to Inti Landauro at inti.landauro@wsj.com

Stocks mentioned in the article : Sanofi, Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/22 REGENERON PHARMACEUTICALS : Assigned Patent
09/20 REGENERON PHARMACEUTICALS : Teva buys rights to Regeneron chronic pain drug for ..
09/20 REGENERON PHARMACEUTICALS INC : Entry into a Material Definitive Agreement (form..
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
09/14 REGENERON PHARMACEUTICALS INC : Change in Directors or Principal Officers (form ..
09/09 REGENERON PHARMACEUTICALS : Findings from Regeneron Pharmaceuticals Reveals New ..
09/09 REGENERON PHARMACEUTICALS : Patent Application Titled "Syringe Systems, Piston S..
09/01 REGENERON PHARMACEUTICALS : Patent Application Titled "Remotely Activated Drug D..
09/01 REGENERON PHARMACEUTICALS : Announces Agreement with BARDA for the Manufacturing..
More news
Sector news : Bio Therapeutic Drugs
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/13DJCREDIT MARKETS : Apple, Daimler on BOE List -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01:50a Amgen's New Products Have Ample Insurance Coverage In The U.S.
09/25 TEVA : Buy For Today's Value And Tomorrow's Growth
09/23 Fovista Results Could See Novartis Dig Deep, And Gilead's NASH Data
09/22 In Teva, Regeneron Finds Its Sanofi For Pain
09/21 Regeneron Pharmaceuticals (REGN) Presents at Bank of America Merrill Lynch 20..
Advertisement
Financials ($)
Sales 2016 5 073 M
EBIT 2016 1 798 M
Net income 2016 731 M
Finance 2016 961 M
Yield 2016 -
P/E ratio 2016 67,41
P/E ratio 2017 46,27
EV / Sales 2016 8,33x
EV / Sales 2017 6,92x
Capitalization 43 212 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 468 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, CEO & Class I Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Class I Director & Chief Scientific Officer
Charles A. Baker Independent Class III Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..-24.40%43 212
AMGEN, INC.7.68%130 813
GILEAD SCIENCES, INC.-19.59%107 381
CELGENE CORPORATION-8.63%84 821
VERTEX PHARMACEUTICALS..-27.97%22 456
ACTELION LTD21.56%18 675
More Results